Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1

Background In 2015, herpes simplex virus 1 (HSV-1)-derived talimogene laherparepvec (T-VEC) was the first oncolytic virus approved by the US Food and Drug Administration as a therapeutic agent for cancer treatment. However, its antitumor application is limited to local treatment of melanoma, and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cellular & molecular immunology 2022-04, Vol.19 (4), p.516-526
Hauptverfasser:	Pan, Chaohu, Cai, Qiaomei, Li, Xiaorong, Li, Lili, Yang, Liping, Chen, Yu, Liu, Junxiao, Liu, Wancheng, Gao, Meiling, Sui, Tianqi, Wang, Xiaoyang, Fan, Huiming, Ruan, Jiayin, Shi, Yueyue, Chen, Saihua, Cheng, Lucy S., Liu, Jiayong, Yang, Heng, Cheng, Genhong
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/251 631/67/1858 Animal models Animals Antibodies Antitumor activity Antiviral activity Apoptosis Basic-Leucine Zipper Transcription Factors - genetics Biomedical and Life Sciences Biomedicine Calreticulin Cell death FDA approval Hemin Herpes simplex Herpes viruses Herpesvirus 1, Human HMGB1 protein Homology Immune response Immunity Immunogenicity Immunology Interferon Lymphocytes T Medical Microbiology Melanoma Metastases Mice Microbiology Oncolysis Oncolytic Virotherapy Oncolytic Viruses - genetics Replication Transcription Tumor cells United States Vaccine Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!